New combo fights back against Tough-to-Treat lung cancer
NCT ID NCT04607954
Summary
This study is testing whether combining two drugs, durvalumab and lurbinectedin, can help control a fast-growing type of lung cancer that has returned or stopped responding to standard treatments. It aims to see if this combination can help patients live longer without their cancer getting worse. The trial is for adults with extensive stage small cell lung cancer whose cancer progressed after initial chemotherapy and immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT LUNG SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.